Phases précoces tumeurs solides
CLEVER-PEPTIDE (IC 2018-06)
Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer.
Paris
CHRISTOPHE LE TOURNEAU